Ceftazidime · CEFTAZIDIME 1 g/1 · Injection, Powder, For Solution · Intramuscular; Intravenous · Hospira, Inc.
NDC 00409-5082-10 · 10 VIAL, SINGLE-DOSE in 1 CARTON / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 00409-5082-16) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
sterile injectable · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is 3× that.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Hospira, Inc. | CEFTAZIDIME 2 g/1 | Jul 15, 2026 | Sep 3, 2026 |
| Hospira, Inc. | CEFTAZIDIME 1 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hospira, Inc. | CEFTAZIDIME 6 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | CEFTAZIDIME 6 g/30mL | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | CEFTAZIDIME 1 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | CEFTAZIDIME 2 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| WG Critical Care, LLC | CEFTAZIDIME 2 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| WG Critical Care, LLC | CEFTAZIDIME 6 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| WG Critical Care, LLC | CEFTAZIDIME 1 g/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Tazicef — NDC 00409-5082-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00409508210.
Free to cite with attribution — see how the data is put together.